Tags

Type your tag names separated by a space and hit enter

Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids.
Am J Cardiol. 2006 Aug 21; 98(4A):71i-76i.AJ

Abstract

Omacor (omega-3-acid ethyl esters; Reliant Pharmaceuticals, Inc., Liberty Corner, NJ) is a highly purified, prescription omega-3 fatty acid formulation with high concentrations of eicosapentaenoic acid (EPA) (465 mg) and docosahexaenoic acid (DHA) (375 mg) in each 1-g capsule, along with 4 mg (6 IU) of vitamin E. At a typical dose of 4 capsules/day, Omacor significantly lowers plasma triglyceride levels either as monotherapy or in combination with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) or fibrates. Omacor also modestly increases plasma levels of low-density lipoprotein cholesterol, increases high-density lipoprotein cholesterol levels, and has favorable effects on lipoprotein particle size and subclass distribution. Omacor is well tolerated, with few side effects other than mild gastrointestinal symptoms. Hyperglycemia, abnormal bleeding, elevations in muscle or liver enzymes, and/or abnormalities in kidney or nerve function have not been reported. Through its intensive purification process, Omacor has minimal "fishy" smell and taste, and it has not been reported to cause hypervitaminosis or illness due to exposure to environmental toxins. Omacor provides a safe, effective, well-tolerated approach to management of hypertriglyceridemia.

Authors+Show Affiliations

L-MARC Research Center, Louisville, Kentucky 40213, USA. HBaysMD@aol.com

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16919519

Citation

Bays, Harold. "Clinical Overview of Omacor: a Concentrated Formulation of Omega-3 Polyunsaturated Fatty Acids." The American Journal of Cardiology, vol. 98, no. 4A, 2006, pp. 71i-76i.
Bays H. Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. Am J Cardiol. 2006;98(4A):71i-76i.
Bays, H. (2006). Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. The American Journal of Cardiology, 98(4A), 71i-76i.
Bays H. Clinical Overview of Omacor: a Concentrated Formulation of Omega-3 Polyunsaturated Fatty Acids. Am J Cardiol. 2006 Aug 21;98(4A):71i-76i. PubMed PMID: 16919519.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. A1 - Bays,Harold, Y1 - 2006/05/30/ PY - 2006/8/22/pubmed PY - 2006/9/29/medline PY - 2006/8/22/entrez SP - 71i EP - 76i JF - The American journal of cardiology JO - Am J Cardiol VL - 98 IS - 4A N2 - Omacor (omega-3-acid ethyl esters; Reliant Pharmaceuticals, Inc., Liberty Corner, NJ) is a highly purified, prescription omega-3 fatty acid formulation with high concentrations of eicosapentaenoic acid (EPA) (465 mg) and docosahexaenoic acid (DHA) (375 mg) in each 1-g capsule, along with 4 mg (6 IU) of vitamin E. At a typical dose of 4 capsules/day, Omacor significantly lowers plasma triglyceride levels either as monotherapy or in combination with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) or fibrates. Omacor also modestly increases plasma levels of low-density lipoprotein cholesterol, increases high-density lipoprotein cholesterol levels, and has favorable effects on lipoprotein particle size and subclass distribution. Omacor is well tolerated, with few side effects other than mild gastrointestinal symptoms. Hyperglycemia, abnormal bleeding, elevations in muscle or liver enzymes, and/or abnormalities in kidney or nerve function have not been reported. Through its intensive purification process, Omacor has minimal "fishy" smell and taste, and it has not been reported to cause hypervitaminosis or illness due to exposure to environmental toxins. Omacor provides a safe, effective, well-tolerated approach to management of hypertriglyceridemia. SN - 0002-9149 UR - https://www.unboundmedicine.com/medline/citation/16919519/Clinical_overview_of_Omacor:_a_concentrated_formulation_of_omega_3_polyunsaturated_fatty_acids_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0002-9149(05)02192-2 DB - PRIME DP - Unbound Medicine ER -